A Breakthrough Decades in the Making

For most of the past half-century, a diagnosis of late-stage pancreatic cancer has been, in the words of one patient, a death sentence. That reality shifted on Wednesday, August 26, when the FDA granted expedited approval to a pill that nearly doubles how long patients with advanced pancreatic cancer survive. The drug, called Rasonque (daraxonrasib), is a RAS inhibitor for the most common form of pancreatic cancer — and it was delivered to patients months ahead of schedule.

Pancreatic cancer accounts for a disproportionately high share of cancer deaths despite representing only about 3 percent of all cancer diagnoses. The aggressive disease is typically detected late, and there have been historically limited treatment options that do little to extend a patient’s life. The American Cancer Society estimates about 67,000 new cases will be diagnosed in the United States this year, and more than 52,000 people will die from the disease — a five-year overall survival rate of just 13%.

How the Drug Works — and Why It Took So Long

FDA officials gave expedited approval to the first-of-a-kind pill, which blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — an approach that previously eluded drugmakers for decades. The challenge was structural: the RAS gene acts like an on/off switch controlling how cells grow in the body, and the mutation causes it to get stuck in the “on” position, spurring cells to grow out of control. The proteins generated by RAS mutations are notoriously flat, leaving no obvious place for a drug to grab hold.

The first approvals came less than a decade after researcher Kevan Shokat and colleagues published their 2013 breakthrough, revealing that a “pocket” on a key RAS variant could allow an inhibitor to bind to a target long deemed “undruggable.” Revolution Medicines, founded around that discovery, began human trials in 2022 and moved with remarkable speed. The pivotal Phase 3 data were presented at the 2026 ASCO Annual Meeting plenary session and published simultaneously in the New England Journal of Medicine.

The Numbers — and the Human Face Behind Them

In a late-stage clinical trial of 500 patients, people who received the drug along with standard chemotherapy lived about twice as long — 13.2 months, on average — compared with people who received chemotherapy alone, who survived 6.7 months. This is now considered the new standard of care for patients with previously treated metastatic pancreatic cancer, after clinical trial results showed a doubling of survival compared to chemotherapy as well as improved quality of life for patients.

One of the most prominent voices behind the drug is former U.S. Senator Ben Sasse of Nebraska. Sasse, who was diagnosed with stage-four pancreatic cancer last December, told “60 Minutes” in April that he was part of the clinical trial for daraxonrasib. He called daraxonrasib “a miracle drug,” saying it has helped him live longer and with less pain. His results were striking: he reported a 76 percent reduction in tumor volume over four months. Like any potent cancer therapy, daraxonrasib comes with risks and limitations, and patients may experience side effects such as rash, diarrhea, mouth sores, and fatigue. A one-month supply costs approximately $39,800, the company announced.

What Comes Next

Rasonque is considered one of the more significant breakthroughs in pancreatic cancer in years , but researchers are already looking well beyond it. Daraxonrasib is designed to target cancers driven by a broad range of common RAS mutations, and it is currently being evaluated in four global Phase 3 registrational trials, including three in pancreatic cancer and one in non-small cell lung cancer. Revolution Medicines is running a Phase III trial of daraxonrasib in RAS-mutant non-small cell lung cancer — a large indication where KRAS mutations are present in roughly 25–30% of adenocarcinomas.

For oncologists and patients alike, the approval signals something larger than a single drug. “The FDA approval of Rasonque is a monumental step forward for patients with pancreatic cancer and for the oncology field,” said Revolution Medicines CEO Mark Goldsmith. “For the first time, patients have an approved targeted medicine designed to directly inhibit the main cause of pancreatic cancer, RAS, which has been one of the most intractable disease targets since its discovery decades ago.” With trials now expanding into earlier-stage disease and additional cancer types, the era of RAS-targeted therapy may be just beginning.